Spots Global Cancer Trial Database for vepesid
Every month we try and update this database with for vepesid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | NCT00539500 | Neuroblastoma | Carboplatin Etoposide Melphalan Stem Cell Infus... ClinicMACS | - | M.D. Anderson Cancer Center | |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | NCT00612430 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | NCT00472056 | Lymphoma | Carmustine Etoposide Cytarabine Melphalan Rituximab | - 80 Years | M.D. Anderson Cancer Center | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma | NCT02106988 | Lymphoma | Radiation Thera... Dexamethasone Etoposide phosp... Ifosfamide Mesna Carboplatin | 18 Years - | M.D. Anderson Cancer Center | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors | NCT00984997 | Lung Cancer | Surgery Chest Irradiati... Cisplatin Etoposide Prophylactic Cr... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | NCT00613223 | Gliosarcoma Glioblastoma | Vandetanib and ... | 18 Years - | Duke University | |
| Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases | NCT00513162 | Neuroectodermal... Brain Metastase... Advanced Cancer | Valproate Etoposide | - | M.D. Anderson Cancer Center | |
| Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas | NCT01329900 | Lymphoma | Ofatumumab Ifosfamide Etoposide Mesna G-CSF Stem Cell Colle... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors | NCT00984997 | Lung Cancer | Surgery Chest Irradiati... Cisplatin Etoposide Prophylactic Cr... | 18 Years - 70 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
